Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Press/Media

Period	13 Feb 2023

Media coverage

Title	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
Media name/outlet	NewsR.in
Country/Territory	India
Date	13/02/23
URL	ct.moreover.com/?a=50001271123&p=1gw&v=1&x=orAYVdy9A01JOWfxG_vFcw
Persons	Mauricio Burotto